Robyn Hunter
Direktor/Vorstandsmitglied bei TENAX THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Aktive Positionen von Robyn Hunter
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TENAX THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 28.01.2022 | - |
Independent Dir/Board Member | 28.01.2022 | - | |
Sotio Biotech AS
Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Finanzdirektor/CFO | 01.08.2022 | - |
Karriereverlauf von Robyn Hunter
Ehemalige bekannte Positionen von Robyn Hunter
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
FORTRESS BIOTECH, INC. | Comptroller/Controller/Auditor | 01.08.2011 | 26.06.2017 |
Finanzdirektor/CFO | 26.06.2017 | 16.08.2022 | |
Unternehmenssekretär | 01.06.2011 | 16.08.2022 | |
Treasurer | 01.06.2011 | 16.08.2022 | |
Schochet Associates, Inc. | Finanzdirektor/CFO | 01.01.2006 | 01.05.2011 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Comptroller/Controller/Auditor | 01.08.2004 | 01.01.2006 |
Stackpole Corp. | Treasurer | 01.01.1990 | 01.01.2004 |
MUSTANG BIO, INC. | Unternehmenssekretär | - | - |
Treasurer | - | - | |
AVENUE THERAPEUTICS, INC. | Unternehmenssekretär | - | - |
CHECKPOINT THERAPEUTICS, INC. | Unternehmenssekretär | - | - |
Ausbildung von Robyn Hunter
Union College (New York) | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 9 |
Kanada | 2 |
Tschechische Republik | 2 |
Operativ
Corporate Secretary | 4 |
Director of Finance/CFO | 3 |
Treasurer | 3 |
Sektoral
Health Technology | 8 |
Consumer Services | 2 |
Producer Manufacturing | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
CHECKPOINT THERAPEUTICS, INC. | Health Technology |
AVENUE THERAPEUTICS, INC. | Health Technology |
FORTRESS BIOTECH, INC. | Health Technology |
MUSTANG BIO, INC. | Health Technology |
TENAX THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
Stackpole Corp. | Producer Manufacturing |
Schochet Associates, Inc. | |
Sotio Biotech AS
Sotio Biotech AS BiotechnologyHealth Technology Sotio Biotech AS is a member of the PPF Group and is based in Prague, Czechia. The Czech company is focused on developing cancer immunotherapies and has a robust clinical pipeline that includes a differentiated superagonist of the immuno-oncology target IL-15, currently being tested in phase II clinical trials. The pipeline also includes SOT102, a next-generation claudin-18.2-targeted antibody-drug conjugate, BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors, and other molecules approaching clinical stage such as SOT201, a next-generation PD-1-inhibiting cytokine. Three programs will enter phase I clinical testing within the next 12 months, including SOT201, BOXR1030, and SOT102. | Health Technology |
- Börse
- Insiders
- Robyn Hunter
- Erfahrung